Deep search
Search
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Notebook
Top stories
Sports
U.S.
Local
World
Science
Technology
Entertainment
Business
More
Politics
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
Eli Lilly’s earnings, shares lifted by obesity drug sales
The drugmaker’s financial forecasts topped Wall Street’s expectations, reassuring investors after it overestimated demand for its weight loss medicines in January.
Diabetes and obesity drugs fuel Eli Lilly profit in the final quarter of 2024
Eli Lilly’s profit doubled in the fourth quarter, propelled by its hot-selling diabetes and obesity treatments, and the drugmaker debuted a mostly better-than-expected 2025 forecast.
Eli Lilly expects to beat profit forecasts on obesity drug demand
The world’s biggest drugmaker Eli Lilly has forecast that profits for the year will beat expectations, after two choppy quarters when disappointing sales of its blockbuster weight-loss drugs led to sharp sell-offs in its shares.
Lilly forecasts 2025 profit growth after recent weight-loss drug worries
Eli Lilly forecast annual profit largely above Wall Street estimates on Thursday, providing some relief to investors after another quarter of sales miss for its popular diabetes and weight-loss treatments.
Eli Lilly to release late-stage data on next-generation weight loss drug retatrutide in 2025, earlier than expected
Eli Lilly expects to read out results from a study in people with obesity and osteoarthritis of the knee in 2025.
11h
on MSN
Eli Lilly's rating gets an upgrade to Aa3 by Moody's Ratings
Ratings has upgraded the issuer rating and senior unsecured notes ratings of global pharmaceutical company Eli Lilly and ...
1d
Lilly reassures investors that weight-loss drug demand is strong, shares rise
Eli Lilly on Thursday suggested that demand for its popular diabetes and weight-loss treatments was not a concern, easing ...
Ibj.com
1d
Lilly reports robust Q4, full-year earnings
Lilly's fourth-quarter earnings, released before the market opened Thursday, surpassed analysts' expectations by millions.
Hosted on MSN
1d
What Are Wall Street Analysts' Target Price for Eli Lilly Stock?
With a market cap of $799.5 billion, Indianapolis, Indiana-based Eli Lilly and Company (LLY) is a leading global ...
BizTimes
12d
Eli Lilly’s planned $3 billion investment in Pleasant Prairie called a ‘watershed moment’ for local economy
On an investment spree with billions of dollars’ worth of projects ongoing globally, Indianapolis-based Eli Lilly and Company ...
FiercePharma
1d
Eli Lilly logs massive Q4 revenue jump—but it's not just thanks to Mounjaro and Zepbound
Although Mounjaro and Zepbound have been headlining Lilly’s financial reports in recent years, the company’s roster of ...
2d
Eli Lilly Gears Up For Q4 Print; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts
Analysts expect the Indianapolis, Indiana-based company to report quarterly earnings at $5.08 per share, up from $2.49 per ...
Ibj.com
9d
Lilly’s Omvoh part of company’s expansion into inflammatory bowel disease treatment
The recent U.S. Food and Drug Administration approval for Eli Lilly and Co.'s Omvoh, a new therapy to treat Chron's disease ...
1d
Lilly: Q4 Earnings Snapshot
Lilly expects full-year earnings in the range of $22.50 to $24 per share, with revenue in the range of $58 billion to $61 billion. This story was generated by Automated Insights ( ...
Daily
3d
Lilly India names Winselow Tucker as President, General Manager
Eli Lilly and Company has announced the appointment of Winselow Tucker as President and General Manager for Lilly India, ...
1d
on MSN
Here’s Why Eli Lilly (LLY) Traded Down in Q4
Fred Alger Management, an investment management company, released its “Alger Spectra Fund” fourth quarter 2024 investor ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback